169 completed, 20 unknown, 18 terminated, 13 withdrawn. 241 Phase 2, 37 Phase 1, 18 Phase 3.
Follow Parkinson's Disease: new trials by email Literature Review of Parkinson's Disease trials Research Report on Parkinson's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease MT101-5 - Parkinson's Disease | Phase 2 | Not yet recruiting | Mthera Pharma Co., Ltd. | 120 | 2027-09-01 | 2026-10-16 |
| Prevent Cognitive Decline in GBA-associated Parkinson's Disease Prasinezumab, Sodium Chloride - Parkinson's Disease | Phase 2 | Recruiting | University Hospital Tuebingen | 120 | 2026-10-01 | 2026-10-23 |
| Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease RO7568282, Placebo - Parkinson's Disease | Phase 1 / Phase 2 | Not yet recruiting | Hoffmann-La Roche | 474 | 2026-09-30 | 2026-10-20 |
| RESvEraTrol in Parkinson's Disease (RESET) Trans-Resveratrol - Parkinson's Disease | Phase 2 | Recruiting | Georgetown University | 30 | 2026-09-17 | 2026-09-18 |
| Terazosin And Metabolic Engagement in Parkinson's Disease Terazosin Hydrochloride, Placebo - Parkinson's Disease | Phase 1 / Phase 2 | Withdrawn | Nandakumar Narayanan | 2026-09-01 | 2026-10-07 | |
| Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease UX-DA003 - Parkinson's Disease | Phase 1 / Phase 2 | Not yet recruiting | Shanghai UniXell Biotechnology Co., Ltd | 12 | 2026-08-03 | 2026-07-29 |
| A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations Lu AF28996, Placebo - Parkinson's Disease | Phase 2 | Recruiting | H. Lundbeck A/S | 150 | 2026-07-28 | 2026-09-08 |
| Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS Exercise - Parkinson's Disease, Deep Brain Stimulation | Phase 2 | Recruiting | The Cleveland Clinic | 36 | 2026-07-08 | 2026-10-26 |
| A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With Motor Fluctuations GM1, Placebo - Parkinson's Disease | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 276 | 2026-05-01 | 2026-05-13 |
| Ketamine for Veterans With Parkinson's Disease Ketamine, Remimazolam - Parkinson's Disease | Phase 2 | Recruiting | VA Office of Research and Development | 80 | 2026-03-01 | 2026-04-13 |
| Menthol for Improving Movement and Sleep in Parkinson's Disease Patients Menthol gloves and socks, Placebo gloves and socks - Parkinson's Disease | Phase 2 | Not yet recruiting | Taipei Medical University Hospital | 80 | 2025-12-15 | 2026-01-08 |
| The Safety,Tolerability, Efficacy of XS411 Cell Injection for the Treatment of Primary Parkinson's Disease human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection - Parkinson's Disease | Phase 1 / Phase 2 | Active not recruiting | XellSmart Therapeutics (Shanghai) Co., Ltd. | 39 | 2025-08-05 | 2026-09-30 |
| Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease [18F]PI-2620 - Parkinson's Disease | Phase 2 | Recruiting | Michael J. Fox Foundation for Parkinson's Research | 60 | 2025-05-12 | 2026-08-10 |
| Tenapanor in Synucleinopathy-Related Constipation Tenapanor, Placebo - Synucleinopathy, Parkinson's Disease | Phase 2 | Recruiting | Cedar Valley Digestive Health Center | 30 | 2025-01-01 | 2025-02-10 |
| A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease DSP-1083 implantation, Sham surgery treatment - Parkinson's Disease | Phase 1 / Phase 2 | Recruiting | Sumitomo Pharma America, Inc. | 25 | 2024-12-18 | 2026-10-21 |
| Cilostazol in Parkinson's Disease Cilostazol, Placebo, Standard treatment - Parkinson's Disease | Phase 2 | Unknown | Ain Shams University | 50 | 2024-10-01 | 2024-09-25 |
| A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease VGN-R09b - Parkinson's Disease | Phase 1 / Phase 2 | Active not recruiting | Shanghai Vitalgen BioPharma Co., Ltd. | 39 | 2024-09-02 | 2026-03-31 |
| Imaging Depression in Parkinson's Disease 11C-UCB-J, ketamine hydrochloride - Parkinson's Disease, Major Depressive Disorder | Phase 2 | Recruiting | Yale University | 120 | 2024-09-01 | 2026-03-10 |
| Early Parkinson's Disease Monotherapy With CVN424 CVN424 150 mg, Placebo - Parkinson's Disease | Phase 2 | Completed | Cerevance Beta, Inc. | 64 | 2023-09-11 | 2026-03-23 |
| Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease AAV-GAD - Parkinson's Disease | Phase 1 / Phase 2 | Active not recruiting | MeiraGTx, LLC | 13 | 2023-05-19 | 2026-09-01 |
Showing 20 of 241. Sign in to see all of them.
Parkinson Disease (241) · Dyskinesias (20) · Movement Disorders (7) · Parkinsonian Disorders (6) · Neurodegenerative Diseases (5) · Basal Ganglia Diseases (4) · Motor Activity (4) · Psychotic Disorders (4) · Tremor (4) · Central Nervous System Diseases (3) · Cough (3) · Depression (3) · Alzheimer Disease (2) · Brain Diseases (2) · Cognitive Dysfunction (2)
Synucleinopathies (240) · Brain Diseases (239) · Nervous System Diseases (239) · Central Nervous System Diseases (238) · Basal Ganglia Diseases (237) · Neurodegenerative Diseases (236) · Parkinsonian Disorders (235) · Movement Disorders (234) · Pathological Conditions, Signs and Symptoms (41) · Signs and Symptoms (35) · Neurologic Manifestations (28) · Mental Disorders (15) · Behavior (8) · Pathologic Processes (7) · Dyskinesias (5)
Levodopa (17) · carbidopa, levodopa drug combination (10) · Carbidopa (8) · istradefylline (8) · Apomorphine (7) · perampanel (6) · Sodium Chloride (5) · Donepezil (4) · rotigotine (4) · 3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine (3) · BID protein, human (3) · Deferiprone (3) · Exercise (3) · Pharmaceutical Preparations (3) · Stalevo (3)
National Institute of Neurological Disorders and Stroke (NINDS) (7) · Chang Gung Memorial Hospital (6) · Eisai Inc. (6) · Kyowa Kirin Co., Ltd. (6) · Novartis (5) · Oregon Health and Science University (5) · Biogen (4) · Kyowa Kirin, Inc. (4) · NeuroDerm Ltd. (4) · Otsuka Pharmaceutical Co., Ltd. (4) · University College, London (4) · University of Florida (4) · VA Office of Research and Development (4) · Avid Radiopharmaceuticals (3) · Impax Laboratories, LLC (3)
United States (119) · France (25) · United Kingdom (24) · Germany (22) · Canada (20) · Italy (16) · Israel (12) · Japan (12) · China (10) · Spain (10) · Austria (8) · Taiwan (8) · Sweden (7) · Portugal (6) · Romania (6)
Kyoji Imaoka, Mr (4) · John G. Nutt, MD (3) · Neil Sussman, MD (3) · Ann Neale, RN (2) · Christine Brefel-Courbon, MD (2) · Laurence Salin, MD (2) · Piu Chan, MD, PhD (2)
PMID 36602886, PMID 38588457, PMID 21484867, PMID 24412048, PMID 31356217, PMID 12222941, PMID 12771261, PMID 1454205, PMID 16376913, PMID 17353373, PMID 17940108, PMID 18268187, PMID 18442107, PMID 18519872, PMID 18591063, PMID 19029430, PMID 19077238, PMID 19524477, PMID 19740486, PMID 20345926, PMID 20946640, PMID 20962287, PMID 21123574, PMID 21419704, PMID 21921019, PMID 21989388, PMID 22316445, PMID 22750016, PMID 22822237, PMID 23728174, PMID 23934921, PMID 24251381, PMID 24711047, PMID 25008546, PMID 25227476, PMID 25382161, PMID 25669730, PMID 25689258, PMID 25943368, PMID 26116315, PMID 26171276, PMID 26226067, PMID 26474316, PMID 26697847, PMID 26709292, PMID 27632893, PMID 27837101, PMID 28370447, PMID 28405611, PMID 28469157
2008 (3), 2009 (3), 2016 (3), R01NS021062 (2), 2004 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1), 2025 (1), I01RX003397 (1), IK2RX002938 (1), M01RR000334 (1), R01AG092298 (1), R01AT000941 (1)